To assess the efficacy and safety of treatment modalities for major organ involvement of Behçet's syndrome (BS), in order to inform the update of the EULAR recommendations for the management of BS.

Objective. To assess the efficacy and safety of treatment modalities for major organ involvement of Behçet’s syndrome (BS), in order to inform the update of the EULAR recommendations for the management of BS. Methods. A systematic literature review of all randomized controlled trials, controlled clinical trials, or open label trials assessing eye, vascular, nervous system or gastrointestinal system involvement of BS was performed. If controlled trials were not available for answering a specific research question, uncontrolled studies or case series were also included. Results. We reviewed the titles and abstracts of 3927 references and 161 studies met our inclusion criteria. There were only nine randomized controlled trials. Observational studies with IFN-α and monoclonal anti-TNF antibodies showed beneficial results for refractory uveitis. Meta-analysis of casecontrol studies showed that immunosuppressives decreased the recurrence rate of deep vein thrombosis significantly whereas anticoagulants did not. CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms. Beneficial results for gastrointestinal involvement were obtained with 5-ASA derivatives and AZA as first line treatment and with thalidomide and/or monoclonal anti-TNF antibodies in refractory cases. Observational studies for nervous system involvement showed improved outcome with immunosuppressives and glucocorticoids. Meta-analysis of casecontrol studies showed an increased risk of developing nervous system involvement with ciclosporin-A. Conclusion. The majority of studies related to major organ involvement that informed the updated EULAR recommendations for the management of BS were observational studies.

Management of major organ involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations / Ozguler, Yesim; Leccese, Pietro; Christensen, Robin; Esatoglu, Sinem Nihal; Bang, Dongsik; Bodaghi, Bahram; Çelik, Aykut Ferhat; Fortune, Farida; Gaudric, Julien; Gul, Ahmet; Kötter, Ina; Mahr, Alfred; Moots, Robert J; Richter, Jutta; Saadoun, David; Salvarani, Carlo; Scuderi, Francesco; Sfikakis, Petros P; Siva, Aksel; Stanford, Miles; Tugal-Tutkun, Ilknur; West, Richard; Yurdakul, Sebahattin; Olivieri, Ignazio; Yazici, Hasan; Hatemi, Gulen. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 57:12(2018), pp. 2200-2212. [10.1093/rheumatology/key242]

Management of major organ involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations

Salvarani, Carlo;
2018

Abstract

Objective. To assess the efficacy and safety of treatment modalities for major organ involvement of Behçet’s syndrome (BS), in order to inform the update of the EULAR recommendations for the management of BS. Methods. A systematic literature review of all randomized controlled trials, controlled clinical trials, or open label trials assessing eye, vascular, nervous system or gastrointestinal system involvement of BS was performed. If controlled trials were not available for answering a specific research question, uncontrolled studies or case series were also included. Results. We reviewed the titles and abstracts of 3927 references and 161 studies met our inclusion criteria. There were only nine randomized controlled trials. Observational studies with IFN-α and monoclonal anti-TNF antibodies showed beneficial results for refractory uveitis. Meta-analysis of casecontrol studies showed that immunosuppressives decreased the recurrence rate of deep vein thrombosis significantly whereas anticoagulants did not. CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms. Beneficial results for gastrointestinal involvement were obtained with 5-ASA derivatives and AZA as first line treatment and with thalidomide and/or monoclonal anti-TNF antibodies in refractory cases. Observational studies for nervous system involvement showed improved outcome with immunosuppressives and glucocorticoids. Meta-analysis of casecontrol studies showed an increased risk of developing nervous system involvement with ciclosporin-A. Conclusion. The majority of studies related to major organ involvement that informed the updated EULAR recommendations for the management of BS were observational studies.
2018
57
12
2200
2212
Management of major organ involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations / Ozguler, Yesim; Leccese, Pietro; Christensen, Robin; Esatoglu, Sinem Nihal; Bang, Dongsik; Bodaghi, Bahram; Çelik, Aykut Ferhat; Fortune, Farida; Gaudric, Julien; Gul, Ahmet; Kötter, Ina; Mahr, Alfred; Moots, Robert J; Richter, Jutta; Saadoun, David; Salvarani, Carlo; Scuderi, Francesco; Sfikakis, Petros P; Siva, Aksel; Stanford, Miles; Tugal-Tutkun, Ilknur; West, Richard; Yurdakul, Sebahattin; Olivieri, Ignazio; Yazici, Hasan; Hatemi, Gulen. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 57:12(2018), pp. 2200-2212. [10.1093/rheumatology/key242]
Ozguler, Yesim; Leccese, Pietro; Christensen, Robin; Esatoglu, Sinem Nihal; Bang, Dongsik; Bodaghi, Bahram; Çelik, Aykut Ferhat; Fortune, Farida; Gaudric, Julien; Gul, Ahmet; Kötter, Ina; Mahr, Alfred; Moots, Robert J; Richter, Jutta; Saadoun, David; Salvarani, Carlo; Scuderi, Francesco; Sfikakis, Petros P; Siva, Aksel; Stanford, Miles; Tugal-Tutkun, Ilknur; West, Richard; Yurdakul, Sebahattin; Olivieri, Ignazio; Yazici, Hasan; Hatemi, Gulen
File in questo prodotto:
File Dimensione Formato  
key242.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 592.64 kB
Formato Adobe PDF
592.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167242
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 79
social impact